Nachrichten zu ACELYRIN

Startseite > Aktien > ACELYRIN > Nachrichten

ACELYRIN Aktie

Aktie

ISIN: US00445A1007 WKN: A3EDH4 SYM: SLRN Land Flagge US

USA

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

4,3050

USD

-0,12 %

-0,0050 USD

Letzter Kurs 16:29:44 Nasdaq

Geldkurs

16:29:40

4,3000

USD

200 STK

Briefkurs

16:29:40

4,3100

USD

500 STK

ACELYRIN Aktie kaufen

Kauf

Verkauf

Neueste Nachrichten

ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Su 10.09.24 · globenewswire · ACELYRIN
ACELYRIN, INC. to Participate in Upcoming Investor Conferences 22.08.24 · globenewswire · ACELYRIN
ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results 13.08.24 · globenewswire · ACELYRIN
ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024 06.08.24 · globenewswire · ACELYRIN
Acelyrin-Aktie: +70% in nur 5 Wochen für NBC-Mitglieder 17.07.24 · Sharedeals · ACELYRIN
ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024 05.06.24 · globenewswire · ACELYRIN
ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024 29.05.24 · globenewswire · ACELYRIN
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones 09.05.24 · globenewswire · ACELYRIN
ACELYRIN, INC. Announces Leadership Transition 09.05.24 · globenewswire · ACELYRIN
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024 29.04.24 · globenewswire · ACELYRIN
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights 28.03.24 · globenewswire · ACELYRIN
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease 20.03.24 · globenewswire · ACELYRIN

1
2
3
…
4

ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of ... 560 Leser
ACELYRIN, INC. to Participate in Upcoming Investor Conferences 492 Leser

ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of ... 560 Leser
ACELYRIN, INC. to Participate in Upcoming Investor Conferences 492 Leser
ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses ... 384 Leser
ACELYRIN, INC. Scales for Continued Late-Stage Growth with The Appointment of Dr. Shephard Mpofu as ... 380 Leser
ACELYRIN, INC. Announces Leadership Transition 364 Leser
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones 236 Leser
ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate ... 228 Leser
ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors 200 Leser
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024 164 Leser
Final Deadline Approaching for SLRN Investors: Kessler Topaz Meltzer & Check, LLP Reminds Acelyrin, Inc. (SLRN) Investors of Class Action Lawsuit ... 160 Leser